Expert Opinion on Drug Metabolism & Toxicology

Papers
(The H4-Index of Expert Opinion on Drug Metabolism & Toxicology is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Probing the mechanism of reduced in vivo potency of insulin detemir144
A three-arm clinical study to compare pharmacokinetic and pharmacodynamic similarity of the denosumab biosimilar LY06006 with reference denosumab in healthy male subjects61
Pharmacotherapy in kidney disease: what it takes to move from general guidance to specific recommendations to stratified subgroups of patients - the tale of autosomal dominant polycystic kidney diseas60
Pharmacokinetics of S1P receptor modulators in the treatment of ulcerative colitis55
Tirabrutinib–anthracycline interactions in the brain tumor microenvironment: a focus on metabolic inactivation and resistance54
The impact of genomic variants on patient response to inhaled bronchodilators: a comprehensive update38
Drug metabolizing enzymes and transporters, and their roles for the development of drug-induced liver injury36
The Central Role of Cytochrome P450 Reductase (CPR) in Hyperoxic Lung Injury35
Unraveling Ritlecitinib: an in-depth analysis of JAK3 inhibitor for the treatment of alopecia areata35
Therapeutic drug monitoring of letermovir in allogeneic hematopoietic cell transplant recipients: where are we?32
Guidance for interactions between antiseizure medications28
Comorbidities and the right dose: antipsychotics27
Hormones, microbes, and PrEP drugs in the female genital tract27
A real-world data analysis of topotecan in the FDA Adverse Event Reporting System (FAERS) database26
Azole antifungals and inter-individual differences in drug metabolism: the role of pharmacogenomics and precision medicine25
Immune-mediated liver injury caused by immune checkpoint inhibitors exhibits distinct clinical features that differ from autoimmune hepatitis24
Pharmacokinetics and pharmacodynamics of approved monoclonal antibody therapy for colorectal cancer23
Bioactivity descriptors for in vivo toxicity prediction: now and the future23
In NAMs we trust – an innovative paradigm-shift in risk-based chemicals management for globally harmonized protection goals23
A comprehensive review of the efficacy and safety of ertugliflozin22
Pharmacokinetic and toxicodynamic concepts in idiosyncratic, drug-induced liver injury21
1.2268900871277